![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Schoffski, Patrick; Kubickova, Michaela; Wozniak, Agnieszka; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Switaj, Tomasz; Bucklein, Veit; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Lee, Che-Jui; Speetjens, Frank M.; Nzokirantevye, Axelle; Neven, Anouk und Kasper, Bernd
(2021):
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
In: European Journal of Cancer, Bd. 156: S. 12-23
Schoffski, Patrick; Sufliarsky, Jozef; Gelderblom, Hans; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Rutkowski, Piotr; Lindner, Lars H.; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Cann, Thomas van; Marreaud, Sandrine; Nzokirantevye, Axelle; Collette, Sandra und Wozniak, Agnieszka
(2018):
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
In: Lancet Respiratory Medicine, Bd. 6, Nr. 6: S. 431-441
Schoffski, Patrick; Wozniak, Agnieszka; Escudier, Bernard; Rutkowski, Piotr; Anthoney, Alan; Bauer, Sebastian; Sufliarsky, Jozef; Herpen, Carla van; Lindner, Lars H.; Grünwald, Viktor; Zakotnik, Branko; Lerut, Evelyne; Debiec-Rychter, Maria; Marreaud, Sandrine; Lia, Michela; Raveloarivahy, Tiana; Collette, Sandra und Albiges, Laurence
(2017):
Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
In: European Journal of Cancer, Bd. 87: S. 147-163